Literature DB >> 27780365

Adherence and safety of regorafenib for patients with metastatic colorectal cancer: observational real-life study.

Salvatore Del Prete1, Gregorio Cennamo1, Luigi Leo2, Liliana Montella1, Bruno Vincenzi3, Maria Biglietto4, Francesca Andreozzi2, Antonella Prudente1, Patrizia Iodice1, Clementina Savastano5, Anna Nappi1, Vincenzo Montesarchio2, Raffaele Addeo1.   

Abstract

AIM: In this prospective multicenter real-life observational cohort study, we investigated the acceptance, adherence and safety of regorafenib, in the treatment of metastatic colorectal cancer patients. PATIENTS &
METHODS: A total of 136 patients were recruited at six oncological hospital sites in southern Italy. The adherence to the treatment was measured with patient-completed medication diaries, physician interviews and pill counts.
RESULTS: We found a statistically significant improvement of therapy adhesion by the acceptance questionnaire. The Eastern Cooperative Oncology Group performance status, the level of acceptance, the educational level and the concomitant usage of oral medications influenced the adherence to the treatment.
CONCLUSION: Patients' level of education, concomitant other oral medications and patients' general clinical condition may influence the adherence to regorafenib.

Entities:  

Keywords:  adherence; clinical practice; compliance; metastatic colorectal cancer; oral therapy; regorafenib; safety

Mesh:

Substances:

Year:  2016        PMID: 27780365     DOI: 10.2217/fon-2016-0421

Source DB:  PubMed          Journal:  Future Oncol        ISSN: 1479-6694            Impact factor:   3.404


  12 in total

1.  Impact of anxio-depressive symptoms and cognitive function on oral anticancer therapies adherence.

Authors:  Mélanie Dos Santos; M Lange; R Gervais; B Clarisse; A Capel; M Barillet; J M Grellard; N Heutte; I Licaj; F Joly
Journal:  Support Care Cancer       Date:  2019-01-28       Impact factor: 3.603

2.  Trifluridine/Tipiracil and Regorafenib in Patients with Metastatic Colorectal Cancer: A Retrospective Study at a Tertiary Oncology Center.

Authors:  Anuj K Patel; Ritika Abhyankar; Lauren K Brais; Mei Sheng Duh; Victoria E Barghout; Lynn Huynh; Mihran A Yenikomshian; Kimmie Ng; Charles S Fuchs
Journal:  Oncologist       Date:  2021-10-01

3.  Dose reduction and discontinuation of standard-dose regorafenib associated with adverse drug events in cancer patients: a systematic review and meta-analysis.

Authors:  Alessandro Rizzo; Margherita Nannini; Marco Novelli; Angela Dalia Ricci; Valerio Di Scioscio; Maria Abbondanza Pantaleo
Journal:  Ther Adv Med Oncol       Date:  2020-07-07       Impact factor: 8.168

4.  Incidence and risk of regorafenib-induced hepatotoxicity.

Authors:  Bin Zhao; Hong Zhao
Journal:  Oncotarget       Date:  2017-09-20

Review 5.  Evolution of regorafenib from bench to bedside in colorectal cancer: Is it an attractive option or merely a "me too" drug?

Authors:  Gaurav Goel
Journal:  Cancer Manag Res       Date:  2018-03-06       Impact factor: 3.989

Review 6.  Maximising clinical benefit with adequate patient management beyond the second line in mCRC.

Authors:  Guillem Argiles; Dirk Arnold; Gerald Prager; Alberto F Sobrero; Eric Van Cutsem
Journal:  ESMO Open       Date:  2019-05-13

7.  Factors Associated With Regorafenib Adherence With Metastatic Colorectal Cancer.

Authors:  Kazuyoshi Kawakami; Takeru Wakatsuki; Azusa Soejima; Kazuo Kobayashi; Takashi Yokokawa; Takeshi Aoyama; Kenichi Suzuki; Mitsukuni Suenaga; Kensei Yamaguchi; Ayaka Inoue; Yoshiaki Machida; Toshihiro Hama
Journal:  Patient Prefer Adherence       Date:  2019-10-15       Impact factor: 2.711

8.  Real-World Adherence in Patients with Metastatic Colorectal Cancer Treated with Trifluridine plus Tipiracil or Regorafenib.

Authors:  Anuj K Patel; Victoria Barghout; Mihran A Yenikomshian; Guillaume Germain; Philippe Jacques; François Laliberté; Mei S Duh
Journal:  Oncologist       Date:  2019-10-07

9.  Incidence and risk of hematologic toxicities in cancer patients treated with regorafenib.

Authors:  Bin Zhao; Hong Zhao
Journal:  Oncotarget       Date:  2017-09-23

10.  Personalization of regorafenib treatment in metastatic gastrointestinal stromal tumours in real-life clinical practice.

Authors:  Margherita Nannini; Maria Concetta Nigro; Bruno Vincenzi; Elena Fumagalli; Giovanni Grignani; Lorenzo D'Ambrosio; Giuseppe Badalamenti; Lorena Incorvaia; Raffaella Bracci; Silvia Gasperoni; Maristella Saponara; Lidia Gatto; Valentina Indio; Annalisa Astolfi; Valerio Di Scioscio; Paolo G Casali; Giuseppe Tonini; Massimo Aglietta; Antonio Russo; Guido Biasco; Maria A Pantaleo
Journal:  Ther Adv Med Oncol       Date:  2017-12-19       Impact factor: 8.168

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.